Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Combination of hsa_circ_0004674 and lncRNA OIP5‑AS1 as a novel clinical biomarker used to predict prognosis in patients with osteosarcoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Spandidos Pub.] Country of Publication: Greece NLM ID: 101531947 Publication Model: eCollection Cited Medium: Internet ISSN: 1792-1015 (Electronic) Linking ISSN: 17920981 NLM ISO Abbreviation: Exp Ther Med Subsets: PubMed not MEDLINE
    • Publication Information:
      Original Publication: [Athens : Spandidos Pub.]
    • Abstract:
      Osteosarcoma is a malignant tumor that predominantly occurs in children or adolescents under the age of 20 years old. Metastasis and chemotherapy resistance are two problems in the treatment of osteosarcoma, and the lack of definite biomarkers impairs the course of treatment. In recent years, non-coding RNA, as a biomarker of osteosarcoma, has become an area of research focus. The role of long non-coding RNAs (lncRNAs), such as lncRNA OIP5-AS1, and circular RNAs, such as hsa_circ_0004674, in osteosarcoma have previously been revealed, and the present study investigated their clinical significance. A total of 20 samples were collected from patients with osteosarcoma. The expression levels of lncRNA OIP5-AS1 and hsa_circ_0004674 were analyzed in tumor tissues and patient serum, and their associations with chemotherapy sensitivity, lung metastasis and prognosis were assessed. The results revealed that these two non-coding RNAs were significantly upregulated in the osteosarcoma tissues of patients compared with those in the adjacent tumor tissues. In addition, the expression levels of the two non-coding RNAs were increased in the serum of patients with osteosarcoma compared with those in patients with bone fractures (P<0.01). In patients with lung metastasis or chemotherapy resistance (tumor necrosis rate <90%), the expression levels of the two non-coding RNAs were similarly increased. By plotting the receiver operating characteristic curve, it was revealed that the combination of hsa_circ_0004674 and lncRNA OIP5-AS1 was better than ALP or either non-coding RNA alone in predicting chemotherapy sensitivity and metastasis. Kaplan-Meier survival analysis showed that, in patients with osteosarcoma, higher expression of both non-coding RNAs was associated with worse survival time (log-rank test P=0.006). In conclusion, the combination of hsa_circ_0004674 and lncRNA OIP5-AS1 may be used as a better biomarker than traditional biomarkers, such as ALP, in a clinical setting.
      Competing Interests: The authors declare that they have no competing interests.
      (Copyright: © Zhu et al.)
    • References:
      J Clin Oncol. 2005 Dec 1;23(34):8845-52. (PMID: 16246977)
      Mol Aspects Med. 2019 Dec;70:117-126. (PMID: 31582259)
      Nat Cell Biol. 2020 Jul;22(7):868-881. (PMID: 32483387)
      Cancer. 1997 Jan 15;79(2):245-54. (PMID: 9010097)
      Int J Biol Sci. 2018 Sep 1;14(11):1513-1520. (PMID: 30263004)
      J Oncol. 2019 Jan 1;2019:7035045. (PMID: 30693030)
      Int J Oncol. 2018 Jan;52(1):77-88. (PMID: 29115574)
      Biomed Pharmacother. 2018 Oct;106:1441-1447. (PMID: 30119217)
      Crit Rev Oncol Hematol. 2015 Feb;93(2):103-15. (PMID: 25459666)
      J Bone Oncol. 2015 Oct 30;4(3):80-4. (PMID: 26587373)
      J Cell Biochem. 2019 Jun;120(6):9656-9666. (PMID: 30548308)
      J Cell Physiol. 2019 May;234(5):6927-6939. (PMID: 30204936)
      Cell Death Discov. 2021 Oct 23;7(1):309. (PMID: 34689155)
      J Cell Biochem. 2019 Sep;120(9):15678-15687. (PMID: 31069828)
      Eur J Cancer. 2011 Mar;47(5):784-91. (PMID: 21112772)
      J Cell Mol Med. 2019 May;23(5):3050-3057. (PMID: 30801950)
      Cancer. 2006 Mar 1;106(5):1154-61. (PMID: 16421923)
      J Oral Maxillofac Pathol. 2014 Sep-Dec;18(3):464-8. (PMID: 25949008)
      Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
      Genome Res. 2012 Feb;22(2):183-7. (PMID: 22301132)
      Cancer Lett. 2018 Apr 1;418:41-50. (PMID: 29330104)
      Int J Biol Macromol. 2019 May 1;128:566-573. (PMID: 30703420)
      Biomed Res Int. 2015;2015:160835. (PMID: 26618165)
      Genomics Proteomics Bioinformatics. 2016 Feb;14(1):42-54. (PMID: 26883671)
      Mol Cancer. 2018 May 12;17(1):89. (PMID: 29753317)
      Front Physiol. 2018 Apr 10;9:321. (PMID: 29692736)
      Mol Cancer. 2019 Apr 2;18(1):73. (PMID: 30940151)
      Mol Ther. 2017 Oct 4;25(10):2383-2393. (PMID: 28750740)
    • Contributed Indexing:
      Keywords: biomarker; non-coding RNA; osteosarcoma; prognosis; survival
    • Publication Date:
      Date Created: 20230424 Latest Revision: 20230425
    • Publication Date:
      20240514
    • Accession Number:
      PMC10119984
    • Accession Number:
      10.3892/etm.2023.11907
    • Accession Number:
      37090082